Comparative Pharmacology
Head-to-head clinical analysis: FOSPHENYTOIN SODIUM versus PHENYTEK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOSPHENYTOIN SODIUM versus PHENYTEK.
FOSPHENYTOIN SODIUM vs PHENYTEK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fosphenytoin is a water-soluble prodrug of phenytoin. It is converted to phenytoin, which stabilizes neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting repetitive firing of action potentials and reducing seizure propagation.
Stabilizes neuronal membranes by promoting sodium efflux and inhibiting calcium influx, thereby reducing repetitive firing of action potentials. Enhances GABA-mediated inhibition and modulates voltage-gated sodium channels.
Loading dose: 15-20 mg PE/kg IV at 100-150 mg PE/min; maintenance: 4-6 mg PE/kg/day IV divided every 8-12 hours.
Initial dose: 100 mg orally 3 times daily; maintenance: 300-400 mg/day in 3-4 divided doses. Extended-release (ER) formulation: 300 mg orally once daily for once-daily dosing; may be increased to 400 mg once daily if needed.
None Documented
None Documented
The terminal elimination half-life of fosphenytoin is approximately 15 minutes (range 8-30 minutes) following IV administration; however, the half-life of the active metabolite phenytoin is 20-30 hours (dose-dependent) in adults, requiring careful monitoring for accumulation.
Terminal elimination half-life averages 22 hours (range 7-42 hours). Dose-dependent due to saturable metabolism; half-life increases with higher doses or in hepatic impairment.
Renal excretion of inactive metabolites (primarily fosphenytoin metabolites including phenytoin metabolites) accounts for approximately 80-90% of elimination; less than 5% excreted unchanged in urine; biliary/fecal excretion minimal.
Primarily hepatic metabolism; less than 5% excreted unchanged in urine. Renal excretion of inactive metabolites accounts for ~70-80%, with biliary/fecal elimination of ~20%.
Category D/X
Category C
Anticonvulsant
Anticonvulsant